Get the Stockscreener App
56.38
1.80%
-1.0444
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $56.38, with a volume of 5.81M.
It is down -1.80% in the last 24 hours and down -1.32% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$57.42
Open:
$57.46
24h Volume:
5.81M
Relative Volume:
0.56
Market Cap:
$116.46B
Revenue:
$47.44B
Net Income/Loss:
$-7.26B
P/E Ratio:
-15.70
EPS:
-3.59
Net Cash Flow:
$13.80B
1W Performance:
-4.35%
1M Performance:
-1.32%
6M Performance:
+21.26%
1Y Performance:
+15.92%
1-Day Range:
$56.19
$57.71
1-Week Range:
$56.19
$60.36
52-Week Range:
$39.35
$61.10
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
56.37 | 116.46B | 47.44B | -7.26B | 13.80B | -3.59 |
|
LLY
Lilly Eli Co
|
884.22 | 827.20B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
86.60 | 386.95B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
153.95 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
ABBV
Abbvie Inc
|
191.83 | 341.01B | 56.33B | 4.28B | 15.62B | 2.40 |
|
MRK
Merck Co Inc
|
87.99 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Lecap Asset Management Ltd. Sells 12,891 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
BMS backs out of Dupixent fight, axing asset despite phase 3 win - Fierce Biotech
Consolidated Portfolio Review Corp Invests $2.38 Million in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb Co (BMY) Stock Price Could Reach $66: Morningstar Research - TopNews India
Bristol-Myers Squibb Co (BMY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Jennison Associates LLC - MarketBeat
McAdam LLC Raises Stock Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Why This Drug Titan Tumbled Despite Its Earnings Beat - Investor's Business Daily
Bristol Myers Squibb kicks off $2B cost-cutting campaign - NJBIZ
Bristol Myers Squibb (BMY) Q4 2024 Earnings Call Transcript - AOL
Jim Cramer on Bristol-Myers Squibb (BMY): “First Schizophrenia Drug in 30 Years” - Insider Monkey
Dow Dips 150 Points; Bristol Myers Squibb Issues Weak Outlook - Benzinga
Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts - AOL
Idiopathic Membranous Nephropathy Market Expected to rise, 2034 | Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche, Aspen Global Inc., Astell - Barchart
Bristol Myers gives first peek at closely watched launch of schizophrenia drug - BioPharma Dive
Bristol-Myers Squibb Loses Ground on Announcing Cost Cuts - Baystreet.ca
Bristol Myers forecasts steeper drop in 2025 revenue, shares fall - Yahoo Canada Finance
Earnings call transcript: Bristol-Myers Squibb Q4 2024 beats estimates - Investing.com
Bristol-Myers Squibb Co (BMY) Q4 Earnings: Revenue Surpasses Est - GuruFocus.com
Bristol Myers Squibb Tops Q4 Estimates - The Motley Fool
Bristol Adds to Cost Cutting With Outlook Missing Estimates - Bloomberg
Bristol Myers Squibb delivers solid Q4 performance, FY25 guidance disappoints - ShareCast
Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%. - Yahoo! Voices
Bristol Myers Squibb, amid restructuring, unveils plan to cut another $2B in costs - FiercePharma
Bristol Myers Earnings Are a ‘Tale of 2 Trends’ as Guidance Falls Short. The Stock Is Falling - Yahoo! Voices
Bristol-Myers Squibb Reports Strong Q4 2024 Financial Results - TipRanks
BMS extends its cost-cutting drive by another $2bn - pharmaphorum
Bristol-Myers Squibb (NYSE:BMY) Posts Better-Than-Expected Sales In Q4 But Full-Year Sales Guidance Misses Expectations By Stock Story - Investing.com Canada
Idiopathic Membranous Nephropathy Market Expected to rise, - openPR
Bristol Myers misses expectations for 2025 guidance, shares fall By Investing.com - Investing.com Canada
Bristol Myers: Q4 Earnings Snapshot -February 06, 2025 at 07:23 am EST - Marketscreener.com
Bristol Myers misses expectations for 2025 guidance, shares fall - Investing.com
Bristol Myers Squibb Surprises With Earnings Despite Competitive Challenges - Finimize
Bristol Myers forecasts steeper drop in 2025 revenue, shares fall By Reuters - Investing.com
Bristol-Myers Squibb earnings beat by $0.20, revenue topped estimates - Investing.com India
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance - CNBC
Bristol-Myers Squibb Q4 24 Earnings Conference Call At 8:00 AM ET - Nasdaq
Bristol-Myers Squibb, Amazon And 3 Stocks To Watch Heading Into Thursday - Benzinga
Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q4 Results Tomorrow - Barchart
Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q4 Results Tomorrow By Stock Story - Investing.com Canada
Bristol Myers Squibb call volume above normal and directionally bullish - TipRanks
Is Bristol-Myers Squibb Company (BMY) the Best Wide Moat Stock to Invest In? - Insider Monkey
Bristol-Myers Squibb's SWOT analysis: stock outlook mixed amid pipeline progress - MSN
Mirae Asset Global Investments Co. Ltd. Boosts Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by CENTRAL TRUST Co - MarketBeat
Inlet Private Wealth LLC Has $2.71 Million Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Bristol Myers Squibb, Kyowa Kirin layoffs hit 119 in New Jersey amid separate restructuring campaigns - FiercePharma
Cantor Fitzgerald lifts Bristol-Myers price target to $55 - Investing.com
Greenwood Capital Associates LLC Sells 4,698 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
0.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):